SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as institutional ownership and call option volume surge ahead of the long-awaited 80th event trigger for the Phase 3 REGAL trial. The community remains intensely focused on interpreting the prolonged timeline as a potential sign of drug efficacy, while active debates continue regarding a possible buyout and the future commercial potential of the SLS009 pipeline.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is facing significant volatility following a post-earnings sell-off that some investors attribute to algorithmic trading and profit-taking despite the company beating revenue and earnings expectations. The community is sharply divided, with bulls arguing that strong AI-driven infrastructure orders make the current price a prime buying opportunity, while others express frustration over perceived market manipulation and the disconnect between solid fundamentals and the stock's recent performance.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing intense volatility ahead of its upcoming earnings report, with the community actively debating the company's massive backlog versus concerns over cash burn and potential dilution. Investors remain polarized, with many betting on a post-earnings breakout driven by the company's role in the expanding commercial space sector, while others warn of a possible pullback.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors react to reports of a potential acquisition by private equity firm Silver Lake, driving high trading volume and sparking significant debate over the valuation and future of the software sector. While some traders are capitalizing on the volatility and sector-wide sympathy rallies, others are cautious, debating whether this rumored buyout signals a genuine turnaround for enterprise software or a temporary spike amid lingering AI disruption concerns.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce shares are drawing interest as the community reacts to news of a significant contract win with the U.S. Department of Veterans Affairs, which is being viewed as a validation of its agentic AI platform. While sentiment remains divided, many investors are focused on whether this enterprise deal can help the company navigate broader software sector volatility and prove its AI monetization strategy is gaining traction.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Holdings is seeing intense community debate following its latest financial results, as investors weigh record-breaking revenue growth and a massive backlog against ongoing profitability hurdles and high short interest. Market participants are split between bullish sentiment fueled by aggressive expansion and contract pipelines, and bearish skepticism regarding dilution and the timing of a sustainable bottom.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is currently a focal point for investors as chipmakers aggressively scale AI compute capacity, driving heavy demand for the company's essential semiconductor manufacturing tools. While some community members are betting on continued growth fueled by AI infrastructure needs, others are expressing significant caution, pointing to highly inflated valuations, profit-taking signals, and ongoing debate over the sustainability of current industry-wide capital expenditure levels.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is facing intense community criticism due to a persistent lack of insider buying and concerns over management's ability to pivot toward AI infrastructure. Investors are actively debating the stock's future ahead of earnings, with many pointing to executive compensation and missed operational milestones as primary catalysts for the recent downward pressure.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to the company's Q2 earnings report, which featured a revenue beat and raised EBITDA guidance alongside the announcement of a new supply agreement with a major dialysis operator. While the market has responded positively to these operational milestones, community discussions reflect ongoing skepticism and volatility as shareholders debate the company's long-term growth trajectory and the potential for a share price rebound.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently experiencing significant downward price pressure and high investor frustration following a multi-day sell-off that has wiped out recent gains. The community is actively debating the cause of the declineranging from manipulative short-selling and algorithm-driven trading to concerns over management's capital allocation and future pipeline viabilityas shareholders look ahead to upcoming earnings for clarity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results...

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris Board of...

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity...

Xeris Announces Updates to Its Board of Directors

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board...

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS

Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States...

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements...

$XERS Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.18 down -1700.00% YoY
• Reported revenue of $92.1M up 28.74% YoY
• Xeris Biopharma Holdings tightened its full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting the company's confidence in its portfolio and business trajectory.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

Equity

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERSXeris Biopharma Holdings Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest XERS News